SCHEMBL3006928

SCHEMBL3006928

CCOc1ccc(-c2csc(N3CCN(S(=O)(=O)c4c(C)cc(C)cc4C)CC3)n2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 7/20 0.53
MAPK1 P28482 6/20 0.53
MEN1 O00255 4/20 0.53
KMT2A Q03164 4/20 0.53
SMN1; SMN2 Q16637 6/20 0.51
ALDH1A1 P00352 3/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
POLB P06746 3/20 0.49
MAPT P10636 6/20 0.48
NPSR1 Q6W5P4 2/20 0.48
TSHR P16473 1/20 0.48
HTT P42858 1/20 0.48
USP2 O75604 1/20 0.47
RECQL P46063 1/20 0.47
HSD17B10 Q99714 1/20 0.47
RAB9A P51151 2/20 0.44
NPC1 O15118 1/20 0.44
CDC25A P30304 1/20 0.41
CDC25B P30305 1/20 0.41
CDC25C P30307 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3009327 0.90 LMNA (0.53) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3006224 0.89 RAB9A (0.57) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3004727 0.88 SMN1; SMN2 (0.58) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3012499 0.87 LMNA (0.56) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3651667 0.86 LMNA (0.49) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3003486 0.86 SMN1; SMN2 (0.58) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3019989 0.86 SMN1; SMN2 (0.64) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3019266 0.85 LMNA (0.54) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3015440 0.85 MAPT (0.56) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3008304 0.85 LMNA (0.48) LMNAMAPK1MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA LMNA 80/4885MAPK1 2767/4885MEN1 454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.